Abstract: Malignant pleural mesothelioma (MPM) is a rare form of thoracic malignancy with a poor prognosis. Pleural effusion (PE) occurs in the majority of patients with MPM; however, its impact on MPM outcomes remains controversial. We searched for eligible patients from the Surveillance, … More
Main Navigation Menu
➤ Asbestos Information Overview
➤ North Carolina Asbestos Exposure Work / Job Sites
➤ Mesothelioma, Asbestos Cancers, and Asbestos Diseases
➤ How to Get Legal Compensation for Your Case
➤ Case Evaluation — Free. Confidential. No Obligation.
➤ Some Information Concerning Our Law Firm
➤ A Brief Message from Attorney Tom Lamb
➤ Recent News & Reports: Asbestos / Mesothelioma
➤ Questions Clients Have Asked Us (FAQs)
➤ Sitemap for Asbestos-Mesothelioma.com
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent News & Reports
Diffuse Pleural Mesothelioma: A Challenge in Early Diagnosis
Abstract: We present the clinical case of a 58-year-old female patient, a smoker with occupational exposure to respiratory toxins, who was admitted to our clinic following evaluation in an emergency department, where she was diagnosed with a moderate right pleural effusion. Upon admission, the … More
A Case Report of Peritoneal Mesothelioma as an Acute Abdomen Mimic: A Rare Presentation and Diagnostic Challenges
Abstract: Malignant peritoneal mesothelioma (MPM) is a rare and aggressive cancer often linked to asbestos exposure. This case report presents a 60-year-old man with a history of asbestos exposure who developed MPM, initially presenting with acute abdominal pain, an uncommon mimic of the acute … More
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
Introduction The purpose of this guideline is to provide recommendations for the management of patients with malignant pleural mesothelioma (MPM), an aggressive tumor with a poor prognosis. In the United States, about 3,000 new cases are diagnosed each year. The median overall survival of patients … More
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual checkpoint inhibitor regimens … More
FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
The FDA has approved [ Keytruda (pembrolizumab) ] plus pemetrexed and platinum chemotherapy in the frontline treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. Data from the phase 2/3 KEYNOTE-483 study (NCT02784171) showed that [ Keytruda … More